Recent overview of ocular patents

Recent Patents on Drug Delivery and Formulation

Volumn 6, Issue 2, 2012, Pages 95-106

  Gaudana, Ripal J ^a   Gokulgandhi, Mitan R ^a   Boddu, Sai H S ^b   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Drug delivery; Nanotechnology; Patents; Prodrug; Transporter targeting

Indexed keywords

1,3 DITHIOLANE DERIVATIVE; BIMATOPROST; CALCIUM CHANNEL BLOCKING AGENT; CIPROFLOXACIN; CLOSTRIDIUM TOXIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN A; CYTOKINE; DICLOFENAC; ETOPOSIDE; FLUOCINOLONE; FLURBIPROFEN; GLYCOLIC ACID; HYDROXYICOSATETRAENOIC ACID; INDAZOLE DERIVATIVE; INOSINATE DEHYDROGENASE; INTERLEUKIN 17; INTERLEUKIN 23; KETOROLAC; LIPOPOLYSACCHARIDE; NANOPARTICLE; PEGAPTANIB; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E; QUINIDINE; SMALL INTERFERING RNA; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTERIOR EYE SEGMENT; ARTICLE; BLOOD EYE BARRIER; CORNEA DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IMPLANT; DRUG INDUSTRY; DRUG RELEASE; DRY EYE; EFFUSION; EYE DISEASE; EYE INFLAMMATION; GLAUCOMA; HUMAN; HYDROGEL; IONTOPHORESIS; MALE; NONHUMAN; PATENT; PIGMENT EPITHELIUM; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; RAT; RETINA MACULA AGE RELATED DEGENERATION; SUSTAINED RELEASE FORMULATION; UNITED STATES; UVEITIS; VISUAL DISORDER; VITREORETINOPATHY; WOUND;

EID: 84861670953     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221112800672921     Document Type: Article

References (104)

1. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010; 12(3): 348-60.
2. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: Impacts of membranes and barriers. Expert Opin Drug Deliv 2008; 5(5): 567-81.
3. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: Challenges and opportunities. Expert Opin Biol Ther 2003; 3(1): 45-56.
4. Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal diseases. Curr Eye Res 2011; 36(12):1069-77.
5. Barot M, Gokulgandhi MR, Haghnegahdar M, Dalvi P, Mitra AK. Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells. J Ocul Pharmacol Ther 2011; 27(6):553-9
6. Majumdar S, Mitra AK. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin Drug Deliv 2006; 3(4):511-27.
7. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26(5):1197-216.
8. Naik R, Mukhopadhyay A, Ganguli M. Gene delivery to the retina: Focus on non-viral approaches. Drug Discov Today 2009; 14(5-6): 306-15.
9. Collier, R.J., Jr., Kapin, M.A., Desantis, L., Jr. Use of betaadrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina. WO2001043737 (2001).
10. Paul Schimmel, K.W., Martin, F. Tryptophanyl-tRNA synthetasederived polypeptides useful for the regulation of angiogenesis. US2319822 (2007).
11. Collier, R.J., Jr., Kapin, M.A., Helliberg, M.R., Dean, A.N., Thomas, R. Compounds with 5-HT1A activity useful for treating disorders of the outer retina. WO2001070222 (2001).
12. Donovan, S. Intravitreal botulinum toxin implant. US2004752871 (2004).
13. Donello, J.E., Dana, P. Ocular therapy using sirtuin-activating agents. US20060371117 (2006).
14. Barker, R.C., Lang, J.C., Stone, R.P. Treatment of AMD with combination of ingredients. US2004019577 (2004).
15. Cua, D.J., Kastelein, R.A., Tsai, V.T., Caspi, R., Silver, P., Luger, D. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease. US2006033840 (2006)
16. Matsuoka, H., Nishimura, K., Seike, H., Aono, H., Murai, M. Angiogenesis inhibitor. US7741346 (2010).
17. Kansara V, Hao Y, Mitra AK. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. J Ocul Pharmacol Ther 2007; 23(4):321-34.
18. Mitra, A.K., Majumdar, So., Jain, R., Nashed, Y. Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux. US20060135438 (2006).
19. Hughes, P.M., Olejnik, O., Chang-Lin, J.-E. Compositions and methods for the intraocular transport of therapeutic agents. US7714024 (2010).
20. Rothbard, J.B., Wender, P.A., McGrane, P. L., Sista, L.V.S., Kirschberg, T.A. Compositions and methods for enhancing drug delivery across and into ocular tissues. US20070213277 (2007).
21. Michael, E., Garst, J.S.A. Methods and compositions for drug delivery. US6350780 (1999).
22. Marcus, D.M., Chu, C.K. Methods and compositions for treatment of macular and retinal disease. US7259180 (2007).
23. Rabinovich-Guilatt, L., Lambert, G. Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye. US20070280995 (2007).
24. Hughes, P.M., Olejnik, O. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug. US20050009910 (2005).
25. Sheibani, N., Albert, D.M. Methods and compositions for treating diseases associated with neovascualrization. US20080076742 (2008).
26. Santini, J., John, T., Cima, M.J., Sheppard, Jr., N.F., Herman, S.J. Implantable, tissue conforming drug delivery device. US7582080 (2009).
27. Kauper, K., Stabila, P., Tao, W. Micronized device for the delivery of biologically active molecules and methods of use thereof. US20070154524 (2007).
28. Utecht, R.E., Kloster, K.L., Downey, T.M., Haberer, B.R., Youso, P.D., Chang, J.N. Novel biomaterials and a method for making and using same. US20080207561 (2008).
29. Heller, J., Schacht, E., Toncheva, V. PEG-polyacetal and PEGpolyacetal-POE graft copolymers and pharmaceutical compositions. US20060235161 (2006).
30. Ashton, P., Guo, H. Sustained release device and method for ocular delivery of adrenergic agents. US20040208910 (2004).
31. Lindgren, D., Mitra, A.K. Ultrasound-mediated transcleral drug delivery. US20080177220 (2008).
32. Li, X., Jasti, B., Mahalingam, R. Ocular agent delivery systems. US20080132444 (2008).
33. Campbell, K.M., Calias, P., Cook, G.P., Ganley, M.A. Controlled release microparticles. WO2007130134 (2007).
34. Liu, J.-J., Tseng, Y.-L., Shih, S.-F., Guo, L., Hong, K. Sustained releasing composition via local injection for treating eye diseases. US20080118500 (2008).
35. Hofland, H., Bongianni, J., Wheeler, T. Ophthalmic liposome compositions and uses thereof. US20040224010 (2004).
36. Calias, P., Cook, G.P., Shima, D.T., Adamis, A.P., Ng, Y.-S., Robinson, G.S., Turner, D.I., Ganley, M.A. Enhanced biologically active conjugates. US20050260651 (2005).
37. Rabinovich-Guilatt, L., De Kozak, Y., Dubernet, C., Lambert, G., Benita, S., Couvreur, P., Behar-Cohen, F. Use of emulsions for intra and periocular injections. US20060002963 (2006).
38. Higuchi, J., Li, S. Kevin, H., William, I., Hastings, M.S. Methods and devices for sustained in-vivo release of an active agent. US20060088515 (2006).
39. Loftsson, T., Stefánsson, E. Cyclodextrin nanotechnology for ophthalmic drug delivery. US7893040 (2011).
40. Prow TW. Toxicity of nanomaterials to the eye. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 2(4): 317-33.
41. Brandt, C.R., Kalil, R.E., Agarwala, S. Replication competent, a virulent Herpes simplex virus as a vector for neural and ocular gene therapy. US6106826 (2000).
42. Hauswirth, W.W., Campochiaro, P.A., Berns, K.I. Raav vector compositions and methods for the treatment of choroidal neovascularization. WO2003080648 (2003).
43. Vargeese, C., Wang, W., Chen, T., Sweedler, D., Haeberli, P. Polycationic compositions for cellular delivery of polynucleotides. US20050222064 (2005).
44. Fleenor, D.L., Shepard, A.R., Pang, I.-H. Antagonists of endothelial differentiation gene subfamily 3 (Edg-3, S1p3) receptors for prevention and treatment of ocular disorders. US20100183629 (2010).
45. Chalberg, T.W.J., Blumenkranz, M., Palanker, D.V., Vankov, A., Hule, P. JR., Marmor, M.F., Calos, M.P. Ocular gene therapy using avalanche-mediated transfection. US20070059835 (2007).
46. Briand, P., Perricaudet, M. Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases. US20030086907 (2003).
47. Belanger, D.B. Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye. US6326499 (2001).
48. Klimko, P.G., Hellberg, M.R., Falck, J.R., Conrow, R.E. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders. US6552084 (2003).
49. Klagsbrun, M., Soker, S. Peptide antagonists of vascular endothelial growth factor. US6777534 (2004).
50. Haddox, J.L., Pfister, R.R., Blalock, J.E., Villain, M. Synthetic complementary peptides and ophthalmologic uses thereof US6762166 (2004).
51. Old, D.W., Dinh, D.T. Piperidinyl prostaglandin e analogs. US20050164990 (2005).
52. Woodward, D.F., Krauss, A.H., Burk, R.M., Holoboski, M., Posner, M.F. EP4 agonists as agents for lowering intraocular pressure. US20040102499 (2004).
53. Graff, G., Hellberg, M.R., Yanni, J.M. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac. US20020183376 (2002).
54. Spina, J.W.M.K. Intralenticular cataract surgery. US4078564 (1978).
55. First, E.R. Methods and compositions for treating eye disorders. US20040234532 (2004).
56. Fleiszig, S.M.J., McNamara, N.A. Use of lipopolysaccharides to manage corneal infections and wounds. US6984622 (2006).
57. Dreyer, E.B. Calcium blockers to treat proliferative vitreoretinopathy. US20030060510 (2003).
58. Dinh, D. Prostaglandin Analogs. US7427614 (2008).
59. Pershadsingh, H. 1,2-Dithiolane derivatives. US6127394 (2000).
60. Borchardt, A.J., Kania, R.S., Palmer, C.L. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. US7053107 (2006).
61. Kiehlbauch, C.C., Chastain, J.E., Leavitt, D.P., Berardi, R.L. Counter pressure device for ophthalmic drug delivery. US20060047255 (2006).
62. Charles, S.T. Vitreoretinal instrument. US7141048 (2006).
63. Franklin, A. Trans-scleral drug delivery method and apparatus US20050197637 (2005).
64. Robinson, M.R., Csaky, K.G., Yuan, P., Sung, C., Nussenblatt, R.B. Ocular therapeutic agent delivery devices and methods for making and using such devices. US20030175324 (2003).
65. Wong, V., Kochinke, F. Formulation for controlled release of drugs by combining hyrophilic and hydrophobic agents. US7048946 B1 (2006).
66. Wong, V.G., Hu, M.W.L. Methods for treating inflammationmediated conditions of the eye. US20040057979 (2004).
67. Wong, V.G. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor. US20040137034 (2004).
68. Zhou, S.Q., Wilcox, C.D., Liau, C., Valyunin, I. Crystalline polymeric compositions for ophthalmic devices. US20020161437 (2002).
69. Wong, V.G., Berger, Jr. D.E. Controlled-release biocompatible ocular drug delivery implant devices and methods. US6331313 (2001).
70. Abreu, M.M.A.M. Contact device for placement in direct apposition to the conjunctive of the eye. US6312393 (2001).
71. Karakelle, M., Brunstedt, M.R. Carrageenan viscoelastics for ocular surgery. US20040019010 (2004).
72. Elson, C.M., Kydonieus, A., Adherent, N. OCarboxymethylchitosan drug delivery devices for moist tissue and methods of their use. US6809085 B1 (2004).
73. Steven, B., Renner, M.J. Drug delivery device. US7211272 (2007).
74. Greenberg, R. Implantable drug delivery device. US20020188282 (2002).
75. Ousler, G.W., Chapin, M.J., Abelson, M.B. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions. US20080261890 (2008).
76. Gadd, M.E., Graff, G. Modulation of polysialylated neural adhesion molecules (Psa-ncam) as a regulator of ocular disease. US20080132451 (2008).
77. Stephen, P., Bartels, T.T.L., Afshin S., Yongqing, L. Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use. US20080125377 (2008).
78. Alam, A., Reichel, E., Busbee, B. Aqueous gel formulation and method for inducing topical anesthesia. US20080020044 A1 (2008).
79. Furfine, E., Dix, D., Graham, K.S., Frye, K. VEGF antagonist formulations suitable for intravitreal administration. US20070293432 (2007).
80. Prausnitz, M.R., Jiang, N., Edelhauser, H.F. Method for drug delivery to ocular tissue using microneedle. US20070260201 (2007).
81. Yamamoto, R., Conston, S.R., Sierra, D. Apparatus and formulations for suprachoroidal drug delivery. US20070202186A1 (2007).
82. Bhushan, R., Gin, J.B. Prevention and treatment of ophthalmic complications of diabetes. US20100069335 (2010).
83. Dor, P.J., Mudumba, S., Nivaggioli, T., Weber, D.A. Formulations for ocular treatment. US20060182771 (2006).
84. Carrasquillo, K.G., Adamis, A.P., Miller, J.W., Gragoudas, E.S. Drug delivery systems and use thereof. US20050175708 (2005).
85. Chen, J., Liu, Y. Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye. US20030212090 (2003).
86. Thornion, S.P., Troyer, E. Treatment for dry eye syndrome. US20060088600 (2006).
87. Gorsek, W.F., Boynton, B. Eyesight enhanced maintenance composition. US6649195 (2003).
88. Abelson, M.B., Gomes, P.J., Chapin, M.J. Novel topical ophthalmic formulations. US20050239745 A1 (2005).
89. Lin, H.-R., Sung, K.-C. Ophthalmic drug delivery formulations and method for preparing the same. US6511660 (2003).
90. Inana, G., McLaren, M. Methods and compositions for detecting and treating retinal diseases. US20090144839 (2009).
91. Stout, J.T., Appukuttan, B. Lentiviral vector-mediated gene transfer and uses thereof. US20060062765 (2006).
92. Davidson, B., Jolly, D.J., Sauter, S.L., Stein, C.S., Dubensky, T.W. Jr., Heth, J.A. Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders. US20030223963 (2003).
93. Manning, W.C.J., Dwarki, V.J., Rendahl, K., Zhou, S., McGee, L.H., Lau, D., Flannery, J.G., Miller, S.S., Wang, F., Di Polo, A. Use of recombinant gene delivery vectors for treating or preventing diseases of the eye. US20020194630 (2002).
94. Bech-Hansen T, N., Margaret, J. Retinal calcium channel (alpha)1F-subunit gene. US6670465 (2003).
95. Murray, J.C.S.E. Methods and compositions for the diagnosis and treatment of cataracts. US6306586 (2001).
96. Feinstein, E., Skaliter, R. Inhibitors of RTP801 and their use in disease treatment. US20110098337 (2011).
97. Jorgensen, J.R. Treatment of Retinopathies using Gfra3 agonists. US20080260702 (2008).
98. Feinstein, E., Mett, I. Therapeutic uses of inhibitors of RTP801L. US20100168204 (2010).
99. McDaniel, D.H. System and method for photodynamic cell therapy. US20060265030 (2006).
100. Yanni, J.M., Gamache, D.A., Miller, S.T. Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells. US20060217325 (2006).
101. Walter, M.A., Jordan, T., Raymond, V. Novel mutations in the freac3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis. US20030013087 (2003).
102. DeHazya, P., Chen, W. Gene therapy for dry eye syndrome. US20030087850 (2003).
103. Flannery, J.G., Hauswirth, W.W. Expression of glial-derived neurotrophic factor for treatment of diseases of the eye. US20030129164 (2003).
104. Heller, R., Jaroszeski, M.J., Gilbert, R.A., Hauswirth, W.H. electroporation device and method for delivery to ocular tissue. US20050277868 (2005).